Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL)—the most common ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...
A study published in the NEJM looks at universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. Dr Rubina Ahmed, Director of Research, Policy and Services, Blood Cancer UK, said: ...
China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech received approval for Priligy ...
ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.
Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...
About one-third of families with a child undergoing treatment for acute lymphoblastic leukemia experienced catastrophic income loss during therapy, with many developing new material hardships over the ...
News-Medical.Net on MSN
Many families of children with leukemia face significant financial hardship during treatment
Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback